Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of the Early Introduction of Everolimus (Certican®) With Low Dose of Cyclosporine in de Novo Kidney Recipients After 1 Month of Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or Females aged 18\~65 years~2. De novo recipients of cadaveric, living unrelated or living related donor kidney transplants~3. Received kidney transplant from aged 10\~65years donor~4. Willing to provide written informed consent~5. Completing study visits according to study protocol~Exclusion Criteria:~1. Recipients of multiple organ transplants~2. Kidney transplant from non-heart beating cadaveric donor / organ donor after cardiac death~3. Recipients of A-B-O incompatible transplants or lymphocyte cross-match positive transplants~4. Recipients of extra-renal solid organ transplants or stem cell transplants~5. Recipient/ donor who are known to have anti-HCV, HIV or HBsAg positive~6. Diagnosed as Cancer within the past 5 years (except complete recovered squamous cell or basal cell skin cancer)~7. Drug Hypersensitivity to investigational drugs or related drugs Females are pregnant and lactating~8. Any of the following laboratory abnormalities at screening:~   * ALT, AST, ALP, total bilirubin \> 3 times the upper limit~  * ANC \< 1,500mm3 or WBC \< 2,500mm3 or platelet \< 100,000 mm3~  * Cholesterol \> 350 mg/dl or 9.0 mmol/L, TG \> 500 mg/dl or 5.6mmol/L

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Everolimus + Low dose CsA +PD (Type: EXPERIMENTAL): None
- Myfortic+ Standard CsA + PD (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).